New Drug Lowers Cholesterol, Fewer Side Effects
- A new drug,ZTA-261,may offer a safer route to treating lipid disorders,according to scientists at Nagoya University in Japan.
- Dyslipidemia, characterized by abnormal lipid levels, affects roughly 10% of the population and elevates the risk of heart attack and stroke.
- The research team, including Masakazu Nambo, Taeko Ohkawa, Ayato Sato, Cathleen Crudden, and Takashi yoshimura, created ZTA-261 to address these issues.
Scientists at Nagoya University have developed a promising new compound, ZTA-261, that may revolutionize the treatment of lipid disorders, specifically targeting dyslipidemia. This new drug shows high selectivity for the THRβ receptor, perhaps offering a safer alternative to existing treatments and reducing the risk of heart attack and stroke. research indicates that in mice, ZTA-261 effectively lowered lipid levels, with fewer side effects compared to conventional methods. addressing the challenges associated with previous therapies, ZTA-261’s design minimizes adverse effects related to bone and heart health. ZTA-261’s potential is highlighted in a recent study. News directory 3 provides updates on this innovative approach. Further studies, including human trials, are needed, but the findings are highly encouraging. Discover what’s next for this groundbreaking development.
New Compound Shows promise in treating Lipid Disorders,Dyslipidemia
updated June 26,2025
A new drug,ZTA-261,may offer a safer route to treating lipid disorders,according to scientists at Nagoya University in Japan. The compound selectively targets the thyroid hormone receptor beta (THRβ), which regulates lipid metabolism.The research, published in Communications medicine, highlights ZTA-261’s potential in treating conditions such as dyslipidemia.
Dyslipidemia, characterized by abnormal lipid levels, affects roughly 10% of the population and elevates the risk of heart attack and stroke. Existing treatments using thyroid hormones face challenges due to side effects stemming from the activation of both alpha (THRα) and beta receptors. While THRα impacts cardiovascular functions, its activation can lead to heart enlargement and bone issues. THRβ, on the other hand, primarily influences lipid metabolism with fewer adverse effects.
The research team, including Masakazu Nambo, Taeko Ohkawa, Ayato Sato, Cathleen Crudden, and Takashi yoshimura, created ZTA-261 to address these issues. Testing in mice showed ZTA-261 had nearly 100 times greater selectivity for THRβ over THRα, far surpassing the 20-fold selectivity of GC-1, another thyroid hormone derivative. Mice treated with natural thyroid hormone T3 showed increased heart weight and bone damage, while those given ZTA-261 did not.
Researchers also assessed liver toxicity by monitoring alanine aminotransferase (ALT) levels. Results indicated no important difference in ALT levels between mice treated with ZTA-261 and those receiving saline, suggesting the drug’s safety.
Ohkawa noted the significant impact of ZTA-261’s THR beta-selectivity on reducing heart and bone toxicity, compared to GC-1 and T3.
Nambo emphasized the importance of precise molecular design in achieving both selectivity and affinity in drug discovery for treating lipid disorders and dyslipidemia.
What’s next
While these results are promising, the scientists emphasize that further studies, including human trials, are necesary before ZTA-261 can be considered for clinical use as a treatment for lipid disorders.